Male Hormone Replacement Therapy

Abbott Labs is under fire after several users of its Androgel® testosterone replacement drug claimed they suffered heart attacks, strokes, and other cardiovascular injuries. The men claimed that Abbott Labs did not properly warn them of the dangers the products might pose to their health.

The FDA is investigating the link between the use of testosterone replacement drugs and cardiovascular events such as stroke, heart attack, and even death. Several studies, including one recently published in the Journal of the American Medical Association, have found a significantly increased risk of cardiovascular events for users of testosterone products.

Products such as Androgel and Axiron® (Eli Lilly) are only approved for treatment of low testosterone when combined with another medical condition, including hypogonadism, genetic problems, problems with the parts of the hypothalamus and pituitary gland, or conditions caused by treatment such as chemotherapy.

However, many products containing testosterone are marketed for off-label use such as to augment sexual performance, muscle tone, energy, and fat metabolism. These uses for the hormone are not approved by the FDA.

Neither Androgel nor Axiron’s labels contain any warning about heart attack or stroke.

Users of these or other male hormone products suffering from symptoms of heart attack or stroke should contact their doctor immediately. These symptoms include:

  • Shortness of breath
  • Palpitations
  • Weakness
  • Dizziness
  • Nausea
  • Sweating
  • Pain in the chest, arm, or below the breastbone

If you or a loved one has suffered from heart attack, stroke, cardiovascular disease, or any of the above symptoms from testosterone replacement therapy, please contact Andrews Thornton Higgins Razmara for a free case evaluation at 1-800-664-1734.

The FDA’s announcement can be found at: http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm

Have a Question?

Please Contact Us using our Contact page
or by calling Toll-Free: (800) 664-1734

Recent Posts about Drugs and Pharmaceuticals

United States v. Barry Cadden – Jury Returns Mixed Verdict in Trial of NECC Co-Founder

United States v. Barry Cadden – Jury Returns Mixed Verdict in Trial of NECC Co-Founder

The jury returned its verdict this morning, finding Barry Cadden, co-founder of the now-defunct [...]
URGENT RECALL: BRAVELLE® FOLLICLE-STIMULATING HORMONE RECALLED FOR LACK OF EFFICACY

URGENT RECALL: BRAVELLE® FOLLICLE-STIMULATING HORMONE RECALLED FOR LACK OF EFFICACY

URGENT RECALL: BRAVELLE® FOLLICLE-STIMULATING HORMONE RECALLED FOR LACK OF EFFICACY In October[...]
Federal Judge Confirms $200 Million Settlement for Victims Injured by Tainted NECC Steroids

Federal Judge Confirms $200 Million Settlement for Victims Injured by Tainted NECC Steroids

Springfield, Mass. - Yesterday, Federal Bankruptcy Judge Henry Boroff ruled in open court confirming[...]
No thumbnail available

Male Testosterone Supplements Linked to Increased Risk of Heart Attack & Stroke

Abbott Labs is under fire after several users of its Androgel® testosterone replacement drug cla[...]
Unexpected Breast Growth from Risperdal Traumatizes Young Men

Unexpected Breast Growth from Risperdal Traumatizes Young Men

Just before the first trial involving Risperdal® (Risperidone) began in Pennsylvania state court[...]
Andrews Thornton Higgins Razmara Investigates ADHD Medications Linked to Priapism in Men

Andrews Thornton Higgins Razmara Investigates ADHD Medications Linked to Priapism in Men

The FDA warns that a class of medications used to treat attention deficit hyperactivity disorder (AD[...]
No thumbnail available

Andrews Thornton Higgins Razmara Hand-Delivers NECC Bankruptcy Claims

In order to guarantee proper and timely filing of over 150 claims in the New England Compounding[...]
No thumbnail available

New Law Helps Ensure Compounding Pharmacy Safety

The FDA has implemented a new law concerning compounding pharmacies that is designed to protect [...]

View all Posts about Prescription Drugs